Monthly Archives: March 2022

11 Stem Cell Research Pros and Cons Vittana.org

Posted: March 25, 2022 at 2:02 am

Stem cell research can be classified into two specific areas: embryonic stem cells and non-embryonic stem cells. Amniotic, induced pluripotent, and adult stem cells do not involve the creation or destruction of a human embryo to have them collected.

Even embryonic stem cells can be collected, to some extent, without the destruction of an embryo. Modern collection techniques include using stem cells that are found in the umbilical cord, in breast milk, or even in bone marrow.

The primary benefit of stem cell research is its clear potential. Since 1868, the idea of using stem cells as a medical treatment has been contemplated in one way or another, especially as we began to understand their full potential. With stem cell therapies, we have the potential to treat injuries, degenerative conditions, or even a genetic disease or disorder.

As for the primary disadvantage of stem cell research, the ethics of collecting embryonic stem cells tends to dominate the conversation. To some people, the idea of destroying an embryo to harvest cells equates to murder. For others, they see the hundreds of thousands of frozen embryos, many of which are simply thrown away after being stored for too long, as wasted potential.

Here are some additional stem cell research pros and cons to review.

1. It could treat several conditions that are virtually untreatable right now. Stem cell research opens numerous avenues for treatments or a cure to be found for several conditions that are either untreatable or without a cure today. Everything from Alzheimers disease to Parkinsons disease to ALS could be improved. People who have a spinal cord injury could receive an injection of stem cells and potentially start the recovery process. Even mental health issues, such as schizophrenia, could one day be treated with stem cell applications.

2. It provides us with greater knowledge. By researching stem cells, we understand more about the growth process of humans. We learn more about how cells form and interact with one another. We can examine pluripotent cells, both induced and embryonic, to see what information is required for them to turn into a specific tissue cell. With a greater understanding of this micro-environment, we can learn more about who we are at our very core.

3. It offers new methods of testing. When new medical treatments are proposed, they must go through multiple stages of testing. This includes animal trials and human trials, which may or may not be successful. As our knowledge of stem cells grows, we could transition testing methods so that only cell populations are examined for a response instead of an innocent animal or a paid human research contributor. That may improve safety, reduce fatalities, and even speed up the approval process.

4. It reduces the risk of rejection. Many stem cell therapies today use the cells that are collected from a patients body. Because the cells are their own, the risk of rejection is reduced or even eliminated. If stem cells could be induced to form into organ tissues, such as a kidney, then the science of organ transplantation could be forever changed. Imagine growing a kidney that is a genetic match instead of trying to find a donor organ that could be rejected, even if a direct match is found. That is the potential of this medical research.

5. It could stop birth defects and mutations before they happen. By understanding the process of stem cell development, it could be possible to change the embryonic development process. Chromosomal concerns, birth defects, and other errors in development could be corrected before birth, giving more newborns a real chance to experience the gift of life. At the same time, the risks of pregnancy loss and health risks to new mothers could be decreased.

1. We have no idea about long-term side effect issues. According to the Canadian Cancer Society, there are several common short-term side effects that are associated with stem cell therapies. They may include infection, bleeding, skin or hair problems, unexplained pain, organ problems, or even the development of a secondary cancer. Every medical treatment provides some risk of a side effect, but this medical technology is so new that we have no idea what the long-term health effects might be.

2. It provides a health risk to everyone involved. Collecting stem cells from an adult carries a medical risk with it. Something could go wrong during the collection process that may reduce the quality of life for the patient. Their life could even be placed at-risk. For embryonic collection, the destruction of the blastocytes that are formed during egg fertilization is required. Since the embryo is technically a different form of human life, there will always be the chance of rejection occurring since the cells are not ones own.

3. Adult stem cells offer limited potential. Our current stem cell research findings indicate that adult stem cells that have already transitioned into specific tissues or formats because of their body location will stay that way. That means stem cells taken from muscle tissue would only be able to create additional muscle tissues. Even if they are induced to be pluripotent, the end result tends to be duplication instead of identification because they have a determined type.

4. It is still an unproven medical technology. There is a lot of hope for stem cell treatments. Hematopoietic stem cell transplantation is performed about 50,000 times annually around the world and the success rate for the treatment is climbing above 90%. Because some forms of stem cell research are classified as illegal or immoral in the United States, however, progress to improve treatments or prove the effectiveness of this medical technology are not as advanced as their potential.

5. It isnt cheap. Stem cell therapies are far from affordable. Because most health insurers classify this type of treatment as experimental, it is rarely a covered procedure. Most treatments that are approved for use in the US cost more than $10,000 per procedure. Some treatment options are six figures. Even the cost of harvesting stem cells from an embryo is a couple thousand dollars. Access to this technology is restricted to socioeconomic means globally and to almost everyone in the United States.

6. Opportunities are limited. Although stem cell research isnt technically forbidden in the US, there are just 19 stem cell lines available for government grants and funding thanks to legislative restrictions that are enacted in 2001. Certain states have begun to draft legislation to completely ban stem cell research, or at least embryonic stem cell research, or at least place major restrictions on the process.

We should examine the ethics of embryonic stem cell research, but we should also examine the benefits it may provide. Adult stem cells, collected from consenting parties, should have no criticism whatsoever. As we move forward in this research, new pros and cons may also require additional contemplation. One thing is for certain: these stem cell research pros and cons show us that humanity is complex, beautiful, and wonderful in many ways.

View original post here:
11 Stem Cell Research Pros and Cons Vittana.org

Posted in Stem Cell Research | Comments Off on 11 Stem Cell Research Pros and Cons Vittana.org

Research Associate, Cancer and Stem Cell Laboratory job with UNIVERSITY OF SYDNEY | 287031 – Times Higher Education

Posted: March 25, 2022 at 2:02 am

About the opportunity

The main focus of the Cancer and Stem Cell Laboratory is to study how normal stem cells are transformed into cancer stem cells and to develop effective new therapies that specifically target and destroy cancer stem cells. These cells, which are often resistant to chemotherapy, are now believed to be the engine driving the growth of cancer and the root cause of treatment resistance and relapse.

The Research Associate will conduct the grant-funded project. Some work may require reasonable additional hours from time to time. Depending on qualifications and expertise the applicant may be appointed at levels equivalent to Academic Level A, step 5-8. Initial appointment is for 12 months, however the position may be extended dependent on funding.

The Research Associate is required to design and develop experiments related to single cell technologies in several ongoing stem cell-associated projects. In collaboration with the bioinformatics team, the Research Associate will perform data analysis and will ensure solid interpretation of the data and potential translational applications of these technologies.

This is an exciting opportunity to be on the forefront of applying single cell technologies to crucial questions in advanced stem cell research.

Your key responsibilities will be to:

About you

Closes 11:59 pm Sunday 10 April 2022

To keep our community safe, please be aware of our COVID safety precautions which form our conditions of entry for all staff, students and visitors coming to campus.

Sponsorship / work rights for Australia

Please note: Visa sponsorship is not available for this position. For a continuing position, you must be an Australian or New Zealand citizen or an Australian Permanent Resident.

Australian Temporary Residents currently employed at the University of Sydney may be considered for a fixed term contract for the length of their visa, depending on the requirements of the hiring area and the position.

Pre-employment checks

Your employment is conditional upon the completion of all role required pre-employment or background checks in terms satisfactory to the University. Similarly, your ongoing employment is conditional upon the satisfactory maintenance of all relevant clearances and background check requirements. If you do not meet these conditions, the University may take any necessary step, including the termination of your employment.

EEO statement

At the University of Sydney, our shared values include diversity and inclusion and we strive to be a place where everyone can thrive. We are committed to creating a University community which reflects the wider community that we serve. We deliver on this commitment through our people and culture programs, as well as key strategies to increase participation and support the careers of Aboriginal and Torres Strait Islander People, women, people living with a disability, people from culturally and linguistically diverse backgrounds, and those who identify as LGBTIQ. We welcome applications from candidates from all backgrounds.

How to apply

Applications (including a cover letter, CV, and any additional supporting documentation) can be submitted via the Apply button at the top of the page.

If you are a current employee of the University or a contingent worker with access to Workday, please login into your Workday account and navigate to the Career icon on your Dashboard. Click on USYD Find Jobs and apply.

For a confidential discussion about the role, or if you require reasonable adjustment or support filling out this application, please contact Scott Walker Recruitment Operations, by email to

The University of Sydney

The University reserves the right not to proceed with any appointment.

Click to view the Position Description for this role.

Continued here:
Research Associate, Cancer and Stem Cell Laboratory job with UNIVERSITY OF SYDNEY | 287031 - Times Higher Education

Posted in Stem Cell Research | Comments Off on Research Associate, Cancer and Stem Cell Laboratory job with UNIVERSITY OF SYDNEY | 287031 – Times Higher Education

Google still has a problem with stem cell and unproven therapies – STAT – STAT

Posted: March 25, 2022 at 2:02 am

Hey, Google: Remember that stem cell problem you tried to fix in 2019 by banning clinics from advertising unproven therapies on your platform?

The solution didnt last. Clinics have adapted, but you havent, leading to widespread use of your search platform by clinics to pitch risky cell injections.

In response to criticism that Google ads for unproven medical offerings were doing harm, the firm adopted a policy in 2019 banning stem cell clinic advertising on its platform. This positive step was part of a larger move against ads selling unproven therapies. Many of the culprits were clinics touting stem cells as treatments for everything from Alzheimers to stroke.

advertisement

After the ban was implemented, people searching for stem cells for COPD or stem cells for neuropathy, to cite just two examples, would no longer see a slew of ads for clinics offering risky, unproven therapies above the Google search results. That worked for a while. But stem cell clinics and others promoting unproven therapies now effectively game Googles search engine to get new customers.

For example, while stem cell clinics may no longer rely on Google ads to hoist themselves to the top of a search results page, some clinics still dominate large swaths of Google search results related to stem cells. In this way, the company is inadvertently sending many people to these clinics to get risky, unproven injections that generally lack FDA approval and, in my view, have no solid scientific or medical foundation.

advertisement

This weakness in Google search has become a public health issue.

The FDA has been largely ineffective at regulating stem cell clinics. Sure, it has issued warnings to a few. But hundreds of these clinics operate in the U.S., with many more worldwide. I hope the FDA becomes more aggressive in regulating the U.S. clinics and there are signs it might in the future but in the meantime Google has a responsibility to tackle its side of the problem.

Whats the issue more specifically?

For many of the most common stem-cell-related searches, Google often spits out top hits listing either websites for stem cell clinics or promotional sites that direct potential customers back to the clinics. That means if you want to know more about stem cells via Google, the search engine will often point you to the profiteering clinics as the supposed authorities.

Those troubling clinics often outrank the National Institutes of Health, the Food and Drug Administration, universities, and other authoritative sites like the Mayo Clinic in Google search results.

Take the two examples I mentioned earlier: stem cells for neuropathy and stem cells for COPD. As I write this, the number one result in each case is a stem cell clinic, which outranks the American Academy of Neurology, the American Lung Association, the NIH, and other truly authoritative sites. In the case of the neuropathy search, almost every result on the first page is a for-profit clinic selling unproven stem cell injections.

In this way, Google is putting vulnerable people at serious risk. At the very least, thousands of people are losing large amounts of money on generally useless treatments. But its more than that. Weve learned in recent years just how big a health gamble going to stem cell clinics can be with reports of patients being blinded, developing the life-threatening blood infection known as sepsis, or having other serious side effects. In rare cases, people have died.

The stem cell problem with Google and how it handles searches related to other unproven therapies ties back into search engine optimization (SEO). Put simply, SEO basically designs a website to perform in the way that Google thinks is best. The websites with the top SEO will almost always rank highest in Google search results, even if they are selling unproven biomedical offerings.

That has to change.

As it now stands, anyone trying to pitch an unproven therapy in theory just has to pump enough money into SEO and Google will usually rank them highly or at the very top in search results, even if the supposed treatment is bogus or dangerous. Google search has effectively become a form of advertising for sketchy health care. In the worst cases, sites ranking the highest with Google may even be selling non-FDA-approved stem cell therapies that are illegal in the U.S.

Google has known about this problem at least since the spring of 2021, but nothing obvious has changed. At that time, I was able to meet with representatives from Google about my concerns. We had an interesting talk, but I didnt get very far advocating for change.

One thing I did learn is that there are at least two sides to Google, and they dont necessarily connect well with each other. Policy people are on one side. Theyre the ones responsible for the ad ban on the stem cell clinics. The search team is on the other side, and they have a very different perspective on things.

The disconnect between the two is exemplified by the fact that many of the same stem cell clinics now barred from advertising on Google are the same ones whose websites are killing it with Google search and in that way presumably driving loads of customers to their profitable but risky clinics.

The problem related to stem cell clinics is just the tip of the iceberg. What Ive been watching with stem cells is going on much more broadly with health-care-related searches in Google. Its fairly easy to find examples of outright snake oil ranking number one in Google search. For instance, Goops page promoting jade eggs ranks best for a search for jade eggs and above the relevant information page of the Cleveland Clinic, and a search for energy healing delivers a page from a practitioner of energy healing above pages debunking the practice.

Those in charge of Google search might argue thats the way it should be. Perhaps theyd say that hopeful searchers want to be directed to purveyors of unproven health care more than to factual information, as reflected in the patterns of what searchers click on. However, the search engine has a greater responsibility to public health than to follow whatever health care hype is popular at any one particular time with the public.

The bottom line is that when it comes to health and health care, Google search is not as logical or safe as many of us might assume.

I believe that part of what is going on is that Google views its search engine as almost sacred. As a result, perhaps it doesnt want to factor in too many ethical or public safety considerations into how its search engine works.

At this point, however, Google cant afford to view its search engine in that hallowed way when it comes to health care. There are just too many websites out there purveying unproven and even risky treatments that Google nonetheless ranks highly.

Is this a solvable problem? Can Google determine what is an unproven medical offering for sale on a website? Could the company distinguish between ongoing clinical research and marketing unproven therapies? Such things could be challenging, but Im confident Google can figure it all out.

In non-health-care areas, like guides to making weapons of mass destruction or certain kinds of porn, Google already takes into consideration whether websites have questionable or illegal content or products for sale. Such websites generally dont turn up in search results. Making searches related to health care safer should be no less important.

Googles continuing stem cell problem is emblematic of a serious, broader problem with unproven biomedical offerings the company needs to address. The solution seems obvious: Selling an unproven treatment must become a consistent, major negative SEO ranking factor incorporated into the companys algorithms.

Otherwise, Google, youre continuing to enable those who sell unproven and sometimes even dangerous medical products and putting the public at risk.

Paul Knoepfler is a professor at the University of California Davis School of Medicine whose research focuses on stem cells and cancer. He writes about ethics, policy, and other matters on his blog, The Niche. Ads on The Niche are limited to reagents for stem cell researchers, not therapy for patients.

Here is the original post:
Google still has a problem with stem cell and unproven therapies - STAT - STAT

Posted in Stem Cell Research | Comments Off on Google still has a problem with stem cell and unproven therapies – STAT – STAT

Medeze Named Frost & Sullivan’s 2021 Company of the Year in the Southeast Asia Stem Cell Banking Industry – PR Newswire

Posted: March 25, 2022 at 2:02 am

The company is at the forefront of innovating stem cell banking, exploring the science of longevity, and offering disruptive solutions to regenerative medicine through its pioneering healthcare technology. As a result, Medeze is reshaping the way age, illness, and incurable diseases are treated.

"Medeze is one of the most experienced mesenchymal stem cell (MSC) banks in the region. The company garnered this reputation thanks to its R&D department's commitment to high-quality research regarding advanced regenerative medicine," said Azza Fazar, Best Practices Research Analyst at Frost & Sullivan. "Medeze Group captures the surging opportunity in stem cell banking by leveraging its offerings for newborns (cord blood, placentaand cord tissue) and adults (adipose tissueand epithelial cells)."

Medeze addresses the growing needs of people who expect to have healthier and longer lives with its highly differentiated services in an industry that is rapidly evolving. The company is taking advantage of this expanding market with valuable solutions for newborns and adults, including adipose tissue, cord blood, placenta, and cord tissue banking.

In addition, its research and development (R&D) abilities position Medeze as a key player in the market and its first-class research is positively impacting patients that seek stem cell procedures. The company is increasing its services by heavily investing in leading-edge technologies and leveraging this R&D.

"Medeze dedicates its energy to R&D to create high-quality customer offerings. It takes pride in its research-backed offerings, which give physicians and patients the confidence they need when selecting the best stem cell banking solution," noted Fazar. "The company strives to expand its offerings based on the latest technologies, such as stem cell printed cornea and hair follicle banking services."

Each year, Frost & Sullivan presents a Company of the Year award to the organization that demonstrates excellence in terms of growth strategy and implementation in its field. The award recognizes a high degree of innovation with products and technologies, and the resulting leadership in terms of customer value and market penetration.

Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan

For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion. Contact us: Start the discussion.

Contact:

Kala Mani. S.Email: [emailprotected]

About Medeze

We are creating a standard of practice that is paving the way for a transformation in the way we look at age and illness. We look towards a day when saving newborn stem cells will be a routine practice and stem cell therapy will be the first line of treatment for many of today's incurable diseases. https://www.medezegroup.com/en/

SOURCE Frost & Sullivan

Read this article:
Medeze Named Frost & Sullivan's 2021 Company of the Year in the Southeast Asia Stem Cell Banking Industry - PR Newswire

Posted in Stem Cell Research | Comments Off on Medeze Named Frost & Sullivan’s 2021 Company of the Year in the Southeast Asia Stem Cell Banking Industry – PR Newswire

Bone Marrow-Derived Stem Cells (BMSCS) Market Report- Growth in Future with Size, Share, Growth, and Key Companies Analysis Cord Blood Registry…

Posted: March 25, 2022 at 2:02 am

The Bone Marrow-Derived Stem Cells (BMSCS) Market research report additionally researches the market regarding volume and income. The report also wraps the promoters in charge of the development of this market. It likewise includes the restrainers that can hamper the development of this market. Further, report talks about on the worthwhile opportunities that can demonstrate development in the market during the estimated time frame i.e. 2022-2029. The report gives the belief system about various components and tendencies influencing the advancement course of the overall Bone Marrow-Derived Stem Cells (BMSCS) Market. An audit of the effect of the authoritative guidelines and approaches on the Bone Marrow-Derived Stem Cells (BMSCS) Market activities is likewise incorporated into this report.

The Bone Marrow-Derived Stem Cells (BMSCS) Market research report offers a total investigation of focused elements that are changing and puts the clients in front of contenders. For simplicity of understanding and better acknowledgment of market drifts, the worldwide Bone Marrow-Derived Stem Cells (BMSCS) Market report conveys the data at local or topographical level. The report additionally edifies the conceivable effect of government laws and strategies on development are incorporated into the report. Keeping the previously mentioned factors in thought alongside the past and current circumstance of the market, the group of expert investigators has created unsurprising business sector pattern to be trailed by the market for a few up and coming years.

Global Bone Marrow-Derived Stem Cells (BMSCS) Market, By Service Type (Sample Preservation and Storage, Sample Analysis, Sample Processing, Sample Collection and Transportation), Application (Personalized Banking Applications, Research Applications, Clinical Applications) Industry Trends and Forecast to 2029.

Get Sample Report + All Related Graphs & Charts (with COVID 19 Analysis) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-bone-marrow-derived-stem-cells-bmscs-market

GlobalBone Marrow-Derived Stem Cells (BMSCS)MarketAnalysis and Size

Bone marrow biopsy is increasingly gaining attraction apart from the western economies. Rising incorporation of advanced healthcare technologies in the developing economies all around the world is carving the way for the growth of the market. Owing to the ease of harvesting and multilinear differentiation potential, bone marrow-derived stem cells (BMSCS) market has a bright future.

Data Bridge Market Research analyses that the bone marrow-derived stem cells (BMSCS) market is expected to undergo a CAGR of 10.90% during the forecast period. This indicates that the market value, which was USD 7.45 billion in 2021, would rocket up to USD 17.04 billion by 2029. Sample Preservation and Storage dominates the service type segment of the bone marrow-derived stem cells (BMSCS) market owing to the rising awareness about the practice of preserving blood cell from a new-born baby for future use.

Competitive Landscape andBone Marrow-Derived Stem Cells (BMSCS)Market Share Analysis

The bone marrow-derived stem cells (BMSCS) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to bone marrow-derived stem cells (BMSCS) market.

Some of the major players operating in the bone marrow-derived stem cells (BMSCS) market are:

GlobalBone Marrow-Derived Stem Cells (BMSCS)MarketDefinition

Bone marrow-derived stem cells (BMSCS) are the multipotent adult stem cells with multilineage differentiation potential. Bone marrow-derived stem cells (BMSCS) help in repairing the broken or damaged bone through secretion of factors that stimulate endogenous repair processes.

Bone Marrow-Derived Stem Cells (BMSCS)Market Dynamics

Drivers

Growing prevalence of problems accompanies with the bone marrow diseases all around the globe is one of the major factors responsible for the growth of the market. In other words, rising incidence rate of leukaemia, aplastic anaemia, myeloproliferative disorders, and others is inducing growth of the market.

Rising expenditure for research and development proficiencies especially in the developed and developing economies will further create lucrative market growth opportunities. Research and development proficiencies being conducted for sample analysis and transportation is also bolstering the market growth rate.

Surging number of public private partnerships for the development of healthcare facilities and infrastructure especially in the developing economies is fostering the growth of the market. Rising introduction of novel technologies for the preservation of stem cells and their storage as a collaborative effort of public and private players is further bolstering the growth of the market.

Opportunities

Furthermore, upsurge in the public-private funding for targetresearchactivities, rising awareness about the benefits of , growing awareness on the therapeutic potential of stem cells, rising development of novel technologies for stem cell preservation, processing and storage, rising geriatric population base and rising product innovations and development owing to technological advancements all around the world will extend profitable opportunities for the market players in the forecast period of 2022 to 2029. Additionally, rise in the birth rate, high operational costs associated with stem cell bankingand increasing per capita expenditure on health care will further expand the markets growth rate in the future.

Restraints/Challenges GlobalBone Marrow-Derived Stem Cells (BMSCS)Market

On the other hand, high cost associated with the research and development proficiencies, limited infrastructural facilities, uneven distribution of medical services and dearth of awareness in the backward economies are expected to obstruct market growth. Also, lack of favorable reimbursement scenario and technology penetration in the developing economies, high operational costs associated with stem cell banking, stringent regulatory framework, limited insurance coverage and regulatory compliance, and lack of suitable infrastructure in low- and middle-income countries are projected to challenge the market in the forecast period of 2022-2029.

This bone marrow-derived stem cells (BMSCS) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market.

COVID-19 Impact onBone Marrow-Derived Stem Cells (BMSCS)Market

COVID-19 had a negative impact on the market. This is because of the significant disruptions experienced by their respective manufacturing companies in the pandemic era. Also, disruptions in the supply-chain operations as a result of various precautionary lockdowns further restricted the growth in this phase. Further the aim of individuals to reduce the non-essential expenses in this pandemic phase narrowed down the scope of growth. Also, restrictions imposed on the movement further created hindrances. However, the future of the market is in good shape.

Table of Contents-Snapshot

Executive Summary

Chapter 1 Industry OverviewChapter 2 Industry Competition by ManufacturersChapter 3 Industry Production Market Share by RegionsChapter 4 Industry Consumption by RegionsChapter 5 Industry Production, Revenue, Price Trend by TypeChapter 6 Industry Analysis by ApplicationsChapter 7 Company Profiles and Key Figures in Industry BusinessChapter 8 Industry Manufacturing Cost AnalysisChapter 9 Marketing Channel, Distributors and CustomersChapter 10 Market DynamicsChapter 11 Industry ForecastChapter 12 Research Findings and ConclusionChapter 13 Methodology and Data Source

For More Insights Get Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-bone-marrow-derived-stem-cells-bmscs-market

GlobalBone Marrow-Derived Stem Cells (BMSCS)Market Scope

The bone marrow-derived stem cells (BMSCS) market is segmented on the basis of service type and application. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Service type

Based on service type, bone marrow-derived stem cells (BMSCS) market is segmented into sample preservation and storage, sample analysis, sample processing, sample collection and transportation.

Application

Bone marrow-derived stemcells(BMSCS) market has also been segmented based on the application into personalized banking applications, research applications and clinical applications. Research applications have been further segmented into disease treatment studies, life science research and drug discovery. Clinical applications have been further segmented into hematopoietic disorders, autoimmune disorders and other diseases.

Read [emailprotected] https://www.databridgemarketresearch.com/reports/global-bone-marrow-derived-stem-cells-bmscs-market

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

Here is the original post:
Bone Marrow-Derived Stem Cells (BMSCS) Market Report- Growth in Future with Size, Share, Growth, and Key Companies Analysis Cord Blood Registry...

Posted in Stem Cell Research | Comments Off on Bone Marrow-Derived Stem Cells (BMSCS) Market Report- Growth in Future with Size, Share, Growth, and Key Companies Analysis Cord Blood Registry…

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Future Business Opportunities 2022-2028 | Caladrius Biosciences, Vericel Corporation,…

Posted: March 25, 2022 at 2:02 am

The Autologous Stem Cell and Non-Stem Cell Based Therapies Market research provides a clear understanding of the markets major geographies, and also the key segments and sub-segments. The study focuses on the state of regional development, including sales volume, cost, and growth volume. The report also gives detailed company descriptions of leading players in the Autologous Stem Cell and Non-Stem Cell Based Therapies industry that are included in Autologous Stem Cell and Non-Stem Cell Based Therapies Market. The research investigates all of the segments based on various parameters such as market dominance, volume, and CAGR. On the fact that it is based, revenue, and sales in the Autologous Stem Cell and Non-Stem Cell Based Therapies market, the analysts have also thoroughly examined different regions such as North America, Europe, and the Asia Pacific. For this report on the Autologous Stem Cell and Non-Stem Cell Based Therapies market, the researchers employed extensive mixed research approaches and technologies.

We Do Offer Sample of this report. Kindly go through the follow information in order to access the report.

** Note This report sample includes:

Brief Introduction to the research report.

Table of Contents (Scope covered as a part of the study)

Top players in the market

Research framework (structure of the report)

Research methodology adopted by Coherent Market Insights

Get a Sample PDF of this Report with the latest Industry trends @https://www.coherentmarketinsights.com/insight/request-sample/523

The analysts have segmented the global market based on raw material, type, application, sales, and region. The study also analyzes the present landscape of the ever-evolving business sector and the present and future of the market. It covers important insights pertaining to established companies operating in the global Autologous Stem Cell and Non-Stem Cell Based Therapies market. The report provides in-depth information by market segment to help you monitor performance and make important decisions for growth and profitability. The report also proposes significant data regarding marketing channel development trends and market position.

Leading players of Autologous Stem Cell and Non-Stem Cell Based Therapies Market including

Caladrius Biosciences, Vericel Corporation, Fibrocell Science, Inc., Genzyme Corporation, BrainStorm Cell Therapeutics, Regeneus Ltd., and Dendreon Corporation.

Get PDF Research Report Brochure @https://www.coherentmarketinsights.com/insight/request-pdf/523

Main Region Coverage: Production, Demand, and Forecasts by Country:

North America (USA, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and other European countries)

Asia Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and other South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, South Africa, and other the Middle East and Africa)

Key Questions Answers in Autologous Stem Cell and Non-Stem Cell Based Therapies Market Report:

Which Manufacturing Morden Development Technology prefer for Autologous Stem Cell and Non-Stem Cell Based Therapies?

Who Are the current Key Players in This Autologous Stem Cell and Non-Stem Cell Based Therapies Industry with Their (Company Profile, Product Information, and Contact Information)?

What is the current as well as future market status of Autologous Stem Cell and Non-Stem Cell Based Therapies?

Who are the key stakeholders in the market?

What Are Industry Dynamics, Challenges, and Opportunities of Autologous Stem Cell and Non-Stem Cell Based Therapies Market?

What Is Economic Impact on Autologous Stem Cell and Non-Stem Cell Based Therapies Industry?

What Was the worldwide Market Status of Autologous Stem Cell and Non-Stem Cell Based Therapies Market with Capacity, Production Value, Cost, and profit?

Buy This Complete Business Report With Flat USD 2000 Off @https://www.coherentmarketinsights.com/promo/buynow/523

In the end, The Autologous Stem Cell and Non-Stem Cell Based Therapies Market Trend for Advancement is examined, along with marketing channels. Finally, the viability of new capital investments is evaluated, and research findings are presented. The Autologous Stem Cell and Non-Stem Cell Based Therapies Market Report also includes information on market share and production growth for each product in the Autologous Stem Cell and Non-Stem Cell Based Therapies market.

Contact:

Coherent Market Insights1001 4th Ave, #3200 Seattle, WA 98154, U.S.Email:[emailprotected]United States of America: +1-206-701-6702United Kingdom: +44-020-8133-4027Japan: +050-5539-1737India: +91-848-285-0837

Continued here:
Autologous Stem Cell and Non-Stem Cell Based Therapies Market Future Business Opportunities 2022-2028 | Caladrius Biosciences, Vericel Corporation,...

Posted in Stem Cell Research | Comments Off on Autologous Stem Cell and Non-Stem Cell Based Therapies Market Future Business Opportunities 2022-2028 | Caladrius Biosciences, Vericel Corporation,…

This Fancy AF Face Cream Was Invented by a Stem Cell Researcher – VICE

Posted: March 25, 2022 at 2:02 am

I remember when the Augustinus Bader brand arrived on the skincare scene. It was a few years ago, and Dr. Bader himself, the accomplished biomedical scientist turned skincare brand founder, hopped on a call with me for an interview for one of New York Citys (now defunct) high fashion retail behemoths. I dont know what I was expectingsomeone pretentious? Unrelatable? Theres just so much schmoozing and so many snake-oil slingers in skincare. But I do remember feeling a massive sigh of relief once he opened up and started divulging the ethos behind his products, which have since amassed such a cult-like followingespecially thanks to one face lotion that is known simply as The Cream amongst skincare junkies.

Augustinus Bader

Bader has over 30 years of medical expertise in stem cell research. In the 1980s, he took his first steps in biomedical health at a burn center before continuing in the field of organ transplantation and then stem cell research. According to Wallpaper, his skincare brand was the by-product of its namesake's development of medical-grade cream, which could heal severe burn injuries to an extent that was previously only possible through skin graftsapplying much of the same science to other types of skin issues, from redness to wrinkles. Maybe thats why it was voted The Greatest Skincare of All Time by WWD Beauty Inc.

His line has the refreshing and rare benefit of coming not from the trend-driven beauty and wellness sector, but from the hard science of a professor who has dedicated his life to understanding the nuances of your skins health. He has a logical, down-to-earth demeanor when speaking about the decision to apply his expertise to luxury skincare, which began with one simple question: If you can heal a full wound, why not heal a wrinkle or dark spot?

The proof is in the pudding, mate; his products have become hugely popular among celebs (Kim Kardashian, Margot Robbie, Alexa Chung, Leonardo DiCaprio, and Jennifer Aniston are all known to be fans), dermatologists, and just consumers in search of skincare products that actually work, with The Cream in particular applauded for its ability to stimulate collagen production and reduce the signs of aging. Its also thanks to the inclusion of Baders TFC8 technology in the various products, or Trigger Factor Complex, which is composed of over 40 ingredients and led by Baders own decades of skincare research and clinical studies. In one four-week trial conducted with 30 participants using his products, the AB team found that after using The Rich Cream, the latest incarnation of Baders signature face lotion, 91 percent of people agreed that their skin looked five years younger and 95 percent found a dramatically improved appearance of fine lines and wrinkles. The Rich Cream is the thicker, more emollient version of the cream, specially formulated for those with dry skinand at $175 for a 30-milliliter bottle, the name is accurate in more ways than one.

Augustinus Bader

Over the years, the AB brand has expanded to include haircare products, serums, and ingestible supplements; theres a powerful, hybrid exfoliator-toner-lotion called The Essence that sounds like it belongs in The Dark Crystal, and collaborations with Spice Girls taste-making celebrities such as Victoria Beckham.

Augustinus Bader

Augustinus Bader

Look, this stuff is expensiveno denying that. But to reiterate, it was developed by a doctor in stem cell research, and the reviews are phenomenal. The real test of ABs worth came once non-celebs started giving them test runs. I am too high-maintenance for a $265 cream (alone), wrote one skeptical beauty editor about The Cream, [but] my skin tone became perceptibly more even and subtly glowy; my post-breakout dark spots faded faster [...] Augustinus Bader really is worth the hype. On Amazon, reviewers of often sold-out AB products praise the staying power of The Creams formula. It is truly amazing and LOOOONG lasting, writes one reviewer, It is not a temporary cream that washes off, and you are back to looking tired and not youthful, it is long lasting and cumulative; another reviewer said [Its] very pricey, so I was nervous. But this stuff works! You need very little, and I swear I have seen a marked improvement in my skin. Additionally, the brand allows customers to donate 5% of their order value to charity.

Perhaps youre looking to treat yourself or a family member to a treat (ATTN: Mothers Day is May 8, Fathers Day is June 19, and my birthday is July 16), or maybe youre just sick of blowing your clams on random skincare products that dont seem to work. If either of those are the case, maybe its time to stop racking up bills from the Sephora checkout line, and time to start putting in an order with the doctor.

Learn more on Augustinus Baders official website.

The Rec Room staff independently selected all of the stuff featured in this story.

More here:
This Fancy AF Face Cream Was Invented by a Stem Cell Researcher - VICE

Posted in Stem Cell Research | Comments Off on This Fancy AF Face Cream Was Invented by a Stem Cell Researcher – VICE

Cell Therapy Market Trends, Revenue, Key Players, Growth, Share and Forecast Till 2028 Reports and Data – Digital Journal

Posted: March 25, 2022 at 2:02 am

The globalcell therapy marketis expected to reach USD 9.24 Billion in 2028 and register a steady revenue CAGR of 5.6% over the forecast period, according to latest report published by Reports and Data. Key factors driving global market revenue growth includeincreasing GMP (Good Manufacturing Practice) certification approvals for cell therapy manufacturing, rising awareness about stem cell therapies, and increasing funds by public and private sectors.

Cellular therapy is a transplantation process carried out by grafting or injecting viable cells into the donors body to replace or repair damaged tissues and cells that cannot be replenished by healthy cells. This therapy is widely used in treating various health conditions such as spinal cord injuries, schizophrenia, Alzheimers, stroke, urinary problems, head injuries, stroke, and infectious diseases, among others. Factors such as rapid increase in the number of clinical trials, improving healthcare facilities, rising disposable income, and healthcare expenditure, and high adoption of human cells for cell therapy research are boosting market revenue growth. In addition, increasing focus on commercializing stem cell treatments and increasing investments to develop enhanced and effective therapies are expected to boost market growth going ahead.

However, factors such as rising ethical concerns about stem cell research, unavailability of well-trained healthcare professionals to handle complex instruments in research laboratories, and budget constraints for certain cell-based research projects are factors that could hamper global market growth to some extent going ahead.

To get a sample copy of the report, click on @https://www.reportsanddata.com/sample-enquiry-form/3269

Some key highlights of the report:

Top Companies Profiled in the Report:

Kolon TissueGene, Inc., Anterogen Co., Ltd., Inc., JCR Pharmaceuticals Co., Ltd., Castle Creek Biosciences, Inc., Mesoblast Ltd., Medipost Co. Ltd., Stemedica Cell Technologies, Inc., Osiris Therapeutics, Inc., PHARMICELL Co., Ltd., Holostem Terapie Avanzate S.r.l., Tameika Cell Technologies, Inc., Cells for Cells, NuVasive, Inc., Vericel Corporation, Celgene Corporation, Thermo Fisher Scientific Inc., Merck KGaA, and Danaher Corporation are key players profiled in the global market report.

Competitive Outlook of theGlobal Cell Therapy Market

The globla Cell Therapy market study focuses on the revenue growth trajectories of the leading companies in this market. This section of the report throws light on the highly competitive landscape of the Cell Therapy market, pointing out the major players. The report further discusses the strategic initiatives undertaken by each of these market players, including mergers & acquisitions, collaborations, joint ventures, new product launches, new business deals, and technological innovations.

To know more about the report, visit @https://www.reportsanddata.com/report-detail/cell-therapy-market

Therapy Type Outlook (Revenue, USD Billion; 2018-2028)

Therapeutic Area Outlook (Revenue, USD Billion; 2018-2028)

Cell Type Outlook (Revenue, USD Billion; 2018-2028)

End-Use Outlook (Revenue, USD Billion; 2018-2028)

Global Cell Therapy Market Report: Table of Contents

Download Summary @https://www.reportsanddata.com/download-summary-form/3269

Regional Outlook of the Global Cell Therapy Market

Request customization of the report @https://www.reportsanddata.com/request-customization-form/3269

Thank you for reading our report. Do connect with us in case of any more queries about the report and its customization. Our team will ensure the report is well suited to cater to your needs.

Explore Latest Trending Research Reports By Reports and Datas

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

John WHead of Business DevelopmentReports And Data | Web:www.reportsanddata.comDirect Line: +1-212-710-1370E-mail:[emailprotected]LinkedIn|Twitter|Blogs

The post Cell Therapy Market Trends, Revenue, Key Players, Growth, Share and Forecast Till 2028 Reports and Data appeared first on Market O Graphics.

See original here:
Cell Therapy Market Trends, Revenue, Key Players, Growth, Share and Forecast Till 2028 Reports and Data - Digital Journal

Posted in Stem Cell Research | Comments Off on Cell Therapy Market Trends, Revenue, Key Players, Growth, Share and Forecast Till 2028 Reports and Data – Digital Journal

Axion BioSystems Acquires Live-Cell Imaging Innovator CytoSMART Technologies – Business Wire

Posted: March 25, 2022 at 1:59 am

ATLANTA--(BUSINESS WIRE)--Axion BioSystems, a leading life sciences tools company focused on advanced live-cell assay systems, announces the acquisition of the Netherlands-based CytoSMART Technologiesan innovator in kinetic live-cell imaging analysis. The collaboration positions Axion for significant expansion in the fields of stem cell research, immuno-oncology, cell-based therapies, and drug discovery.

Since Axion BioSystems inception, our focus has been on developing user-centric products that accelerate scientific discovery, with the specific goal of building innovative systems that monitor cellular activity without disturbing the underlying biology. The Maestro, our flagship bioelectronic assay (BEA) platform, has transformed neurological disease research over the past 14 years. Likewise, our most recent addition to the BEA portfolio is doing the same in groundbreaking fields like immunotherapy, said Tom OBrien, President & CEO of Axion BioSystems. In CytoSMART, we found a company with technology complementary to our own, as well as a partner with the same fundamental objectiveto provide customers with high-quality instruments and powerful software that rapidly advance live-cell research and cell therapy development. We welcome the entire CytoSMART team, and we are excited to add their expertise to our own.

Noninvasively studying the real-time biology of live cells allows scientists to obtain a more complete understanding of the complex processes underpinning health and disease. In their respective arenas, both Axion and CytoSMART have focused on the development of next-generation analysis tools for use in pharmaceutical, academic, and biotechnology research. Along with Axions recent acquisition of UK-based printed electronics manufacturer M-Solv Manufacturing Limited, this latest product portfolio expands the companys offerings and opportunities in a rapidly growing life sciences tools market.

According to Joffry Maltha, CEO of CytoSMART, the mutually beneficial partnership is a natural fit. Axions overall mission and corporate culture align with our efforts to provide scientists around the world with high-quality, easy-to-use products to advance their research goals. With Axions resources and experience, we look forward to accelerating our market growth and product innovation.

About Axion BioSystems

Axion BioSystems is a leading life sciences tools company focused on innovative live-cell assays used to study the function of cells in vitro for drug discovery and disease modeling. The team at Axion BioSystems is dedicated to continuing the advancement of new technologies that accelerate research and further the understanding of biological complexity outside of the body. Axion BioSystems is headquartered in Atlanta, Georgia, USA, and has offices worldwide. Axion has more than 90 employees across its current locations. http://www.axionbiosystems.com

About CytoSMART

CytoSMART Technologies is a specialist in the development and manufacturing of live-cell imaging systems for life science laboratories. The company was founded in 2012 by a team of biologists and engineers who were convinced that a new generation of miniaturized microscopes, powered by artificial intelligence for image analysis, would allow biologists to make discoveries more efficiently and at scale. In 2018, CytoSMART was selected by Microsoft for its prestigious ScaleUp program. CytoSMARTs microscopy solutions are used in research laboratories worldwide. CytoSMART Technologies is headquartered in Eindhoven, the Netherlands, and has more than 50 employees. http://www.cytosmart.com

Originally posted here:
Axion BioSystems Acquires Live-Cell Imaging Innovator CytoSMART Technologies - Business Wire

Posted in Georgia Stem Cells | Comments Off on Axion BioSystems Acquires Live-Cell Imaging Innovator CytoSMART Technologies – Business Wire

ChristianaCare and The Wistar Institute Advance Partnership With New Cancer Research Strategies – ChristianaCare News

Posted: March 25, 2022 at 1:58 am

March 18, 2022

ChristianaCares Helen F. Graham Cancer Center & Research Institute is advancing its historic partnership with the Ellen and Ronald Caplan Cancer Center of The Wistar Institute in Philadelphia, Pennsylvania, with three new research projects under way.

The new research projects consist of a population health study targeting triple negative breast cancer. Other projects focus on a new therapeutic target for epithelial ovarian cancer, the most lethal gynecologic cancer in the developed world, and the development of mini organs derived from stem cells.

Delaware has one of the highest incidence rates of triple-negative breast cancer in the United States. This highly aggressive cancer has few treatment options, because the cells test negative for three known treatment targets estrogen, progesterone and HER2 protein receptors.

Working with patient data from the Graham Cancer Center, researchers are investigating potential contributing factors such as diet, alcohol use and genetic variants among women, and the effects of these on cancer metabolism. The team will also examine spatial relationships between cancer hot spots geographic areas with a higher-than-expected prevalence and modifiable risk factors.

Key resources for the study are blood and tissue samples from the Graham Cancer Centers Tissue Procurement Center and its statewide High-Risk Family Cancer Registry.

The research team will be led by Director of Population Health Research at ChristianaCare Scott Siegel, Ph.D., and Lead Research Scientist Jennifer Sims Mourtada, Ph.D., at the Graham Cancer Centers Cawley Center for Translational Cancer Research (CTCR). They will join Zachary Schug, Ph.D., at Wistars Molecular and Cellular Oncogenesis Program.

The latest study supported by the Graham Cancer Centers Tissue Procurement Program targets KAT6A expression as a novel therapy for ovarian cancer caused by a specific genetic mutation, called PP2R1A.

Epithelial ovarian cancer is the most common form of ovarian cancer and the leading cause of gynecologic cancer deaths in the United States.

Chemoresistance to currently available platinum-based drugs like cisplatin represents a major treatment challenge, as more than 50 percent of affected women ultimately relapse and die from this disease.

Wistars Rugang Zhang, Ph.D., leader of the Immunology, Microenvironment and Metastases Program, is focused on developing novel therapeutics for subtypes of ovarian cancer that currently have no effective therapies and on improving the current standard of care.

Dr. Zhangs previous work suggests that KAT6A signaling plays a critical role in ovarian cancer progression. Targeting this signaling pathway could be an effective strategy for treating ovarian cancer.

Working with Dr. Zhang on this project are Graham Cancer Center gynecologic oncologists Mark Cadungog, M.D., director of Robotic Surgery, and Sudeshna Chatterjee-Paer, M.D., and Cawley CTCRs Stephanie Jean, M.D., director of Gynecologic Oncology Research. Also collaborating with the team is Wistars Alessandro Gardini, Ph.D., assistant professor in the Gene Expression & Regulation Program.

Dr. Sims-Mourtada at the Cawley CTCR will lead a new program to culture organ-specific tissue from stem cells that could change the way diseases are studied and treated.

These so called mini organs or organoids are three-dimensional tissue cultures grown in the lab that replicate the complexity and functions of a specific tissue or organ found in the body.

Organoids offer scientists a better model for how drugs and other therapeutics might interact with a patients particular type of tumor, opening new avenues for precision medicine.

The ability to grow each patients tumor in a three-dimensional organoid along with our capability to create patient-derived xenograft or animal models as part of our PDX core, will allow us to fully capture the effects of genetic as well as gene altering behavioral and environmental influences that are lacking in current research models, said Dr. Sims-Mourtada.

Our collaboration with Wistar to build these programs raises our clinical platform to the next level for studying new cancer biomarkers and treatments.

The Graham Cancer Center made history when it signed a first-of-its-kind agreement in 2011 with The Wistar Institute, pairing a National Cancer Institute, NCI-designated basic research institution with a community cancer center that is also an NCI Community Oncology Research Program (NCORP).

Our partnership with Wistar has attracted national recognition as a model of collaboration that leverages cutting-edge research to benefit cancer prevention and therapy statewide, says Nicholas J. Petrelli, M.D., Bank of America endowed medical director of ChristianaCares Helen F. Graham Cancer Center and Research Institute.

With Wistar, our productive collaborations over the last decade continue to drive discovery research toward clinical trials to benefit patients here at the Graham Cancer Center and in communities everywhere.

The Graham Center has been an ideal partner in our mission, said Dario C. Altieri, M.D., Wistar president and CEO and director of the Ellen and Ronald Caplan Cancer Center. Our scientists at Wistar have access to clinically-annotated primary patient specimens of the highest quality.

As the majority of patients at the Graham Cancer Center are treatment nave, this collaboration affords an opportunity to conduct unique, high impact mechanistic and correlative studies that will ultimately advance important scientific discoveries that hopefully will lead to better cancer therapies.

See the rest here:
ChristianaCare and The Wistar Institute Advance Partnership With New Cancer Research Strategies - ChristianaCare News

Posted in Pennsylvania Stem Cells | Comments Off on ChristianaCare and The Wistar Institute Advance Partnership With New Cancer Research Strategies – ChristianaCare News